Oryzon participates in a R&D European consortium in Parkinson’s disease
Oryzon a Biopharmaceutical company dedicated to the discovery of biomarkers and development of novel therapeutics and diagnostics announced that its CSO, Dr. Tamara Maes, participated at the kick-off meeting of the European Porject DDPDGENES held on January 16 and 17 in Stockholm (Sweden).